Hanmi Pharm’s neutropenia drug Rolontis and Daewoong Pharmaceutical’s Fexuclu Tablet, a new drug for gastroesophageal reflux disease, will jointly win the 23rd Korea New Drug Development Award.
Icure (CEO Choi Young-kwon), which developed ‘Donesive Patch’, a patch for dementia treatment △Hallym Pharmaceutical (CEO, Jeong-jin Kim), which developed ‘Bronpass Tablet,’ an acute bronchitis treatment April Bio (CEO Sang-Hoon Cha), who developed the candidate substance ‘APB-A1’, receives the Technology Export Award.
The Korea New Drug Development Research Association (Chairman Dong-yeon Kim) will hold the ’23rd Korea New Drug Development Awards Ceremony’ at 3:40 pm on the 23rd at the Samjeong Hotel Geranium Hall to celebrate the achievements of domestic pharmaceutical and biotech companies in new drug development and technology export. make a place to
Grand Prize in New Drug Development Division
Hanmi Pharmaceutical Rolontis, Daewoong Pharmaceutical Fexuclu Tablet
Hanmi PharmDeveloped neutropenia treatment Rolontisis the domestic 33rd new drug developed by applying LAPSCOVERY, Hanmi Pharm’s proprietary platform technology that extends the duration of the drug’s efficacy.
Rolontis has superior hematopoietic stem cell differentiation and proliferation efficacy compared to existing products by specific distribution and sustained action in the bone marrow, which is the main target organ.
The company said, “Rolontis plans to apply for a marketing license (BLA) to the US FDA in the first quarter of this year following exporting its technology to the US spectrum in the clinical stage in 2012. said.
Se-chang Kwon, president of Hanmi Pharm, said, “It is very meaningful that Rolontis won the grand prize at the Korea New Drug Development Award before entering the global market worth 4 trillion won. We will nurture it as a new drug,” he said.
Daewoong Pharmaceutical Gastroesophageal reflux disease treatment Fexuclu Tabletis the domestic 34 new drug developed with its own technology.
According to the company, Fexuclu Tablet is a P-CAB (Potassium-Competitive Acid Blocker) formulation that reversibly blocks the proton pump that secretes gastric acid from the stomach wall. has proven
Fexuclu Tablet improved the symptoms of heartburn regardless of day or night from the beginning of administration. In particular, when administered to patients with severe symptoms, it improved heartburn symptoms in three times as many patients as compared to the control group, Esomeprazole.
The company announced that it has already achieved a total of 1.1 trillion won in global technology exports to 15 countries, including the United States, Canada, and Brazil.
Daewoong Pharmaceutical CEO Jeon Seung-ho said, “I would like to thank the company and researchers for their efforts in research and development. We will accelerate exports,” he said.
Award of Excellence in New Drug Development
Icure Donesive Patch, Hanlim Pharmaceutical Bron Pass Tablet
iCureDementia treatment patch developed by Donesive Patchis the world’s first donepezil patch. By changing the route of administration, it is a drug that has increased the value of donepezil, a drug for treating Alzheimer’s-type dementia, from an oral drug, which had to be taken once a day, to a patch that is attached twice a week.
Donesive Patch confirmed the non-inferiority of the patch compared to the existing oral drug through the Phase 3 clinical trial conducted for 24 weeks in regarding 400 patients with mild and moderate dementia in Korea, Taiwan, Australia and Malaysia.
The company said, “It was confirmed that there was no significant difference in effect even for patients taking the existing donepezil oral drug when switching to the patch corresponding to the dosage, thereby improving the convenience of taking the drug and reducing side effects. We expect to be able to convert more than half of the donepezil market to a patch agent,” he said.
Hanlim PharmaceuticalA treatment for acute bronchitis developed by this Bron Pass Tabletis a complex herbal extract containing baekbu root, which is known to be effective in bronchial diseases, by selecting six medicinal ingredients from Cheongsangbohatang, a natural new drug that has been used for bronchial inflammation.
The company said, “In phase 3 clinical trials for patients with acute bronchitis, it showed improvement in non-inferior symptoms, and through clinical trials, it was confirmed that there were no side effects of existing acute bronchitis treatments (antibiotics).”
He also said that it is expected that R&D in the field of natural medicines will be activated through the successful development of BronPass Tablet.
Technology Export Award
April Bio APB-A1
April BioCandidates for the treatment of autoimmune diseases developed by APB-A1is a new drug substance in the field of recombinant protein and antibody drugs.
The company said, “APB-A1 was developed through April Bio’s own platform technology, SAFA (anti-serum albumin Fab-associated), and binds to CD40L, which is mainly expressed in activated T cells, to suppress cellular and humoral immune responses. It has a mechanism of action, so it can be applied to various autoimmune diseases.”
In addition, “In October of last year, a total of $ 448 million (regarding 540 billion won) including a down payment of $ 16 million (regarding 19.2 billion won) and development, licensing and sales milestones to H. Lundbeck A/S, a Danish pharmaceutical company “If APB-A1 is developed as a treatment, we expect to provide more diverse treatment options to patients with thyroid eye disease.”
Korea New Drug Award (KNDA)
This year marks the 23rd anniversary of Korea’s first new drug development award, led by the private sector and sponsored by the government across all industries in Korea.
It was established in April 1999 by the Korea New Drug Research Association to develop the domestic bio-health industry and inspire new drug R&D motivation.
